Welcome to GLIOTRAIN

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics



An estimated 240,000 cases of brain and nervous system tumours are diagnosed every year, worldwide and Glioblastoma (GBM) is the most frequent and aggressive brain tumour. New treatment options and effective precision medicine therapies are urgently required. GLIOTRAIN is a multi-sectoral industry-academia collaboration, funded by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie ITN initiative, that will work to identify novel strategies to treat GBM as well as investigating resistance mechanisms in this devastating disease.

Latest news

GLIOTRAIN consortium members, the University of Stuttgart and YUMAB, awarded grant to establish new approaches in Targeted Drug Delivery to the Brain

GLIOTRAIN investigators Professor Markus Morrison and Dr Gavin Fullstone, from the University of Stuttgart, along with GLIOTRAIN industry partner YUMAB and other partners have been awarded a grant from the Federal Ministry of Education and Research (BMBF, Germany) on the theme of Targeted Drug Delivery.

GLIOTRAIN Translational Research Symposium to take place on the 19th and 26th January 2021

A GLIOTRAIN-organised virtual translational research symposium will take place on the 19th and 26th January 2021. This PhD student training event replaces an in-person event that had been scheduled to take place in Paris in May 2020, but that was unfortunately a casualty of the Coronavirus pandemic. We are now pleased to invite participants to the event in a new, virtual format. To view the programme please click here

GLIOTRAIN consortium member, the Luxembourg Institute of Health (LIH), establishes a collection of preclinical patient-derived brain tumour models to accelerate drug development

Dr Anna Golebiewska and Prof Simone Niclou and GLIOTRAIN ESR Yahaya Yabo from the NORLUX Neuro-Oncology Laboratory at the LIH Department of Oncology (DONC), along with key collaborators, have established a large collection of patient-derived glioma organoids and xenograft models that mimic the specific features of patient brain tumours. The work was undertaken in collaboration with the Centre Hospitalier de Luxembourg (CHL), the Laboratoire National de Santé (LNS), the Luxembourg Centre for System

The Team